Education
About Us
Working with TipRanks
Follow Us
Liminatus Pharma, Inc. (LIMN)
NASDAQ:LIMN
Total Valuation
Liminatus Pharma has a market cap or net worth of $19.16M. The enterprise value is ―.
Market Cap$19.16M
Enterprise Value―
Share Statistics
Liminatus Pharma has 27,064,632 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,064,632
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Liminatus Pharma’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 400.57%.
Return on Equity (ROE)0.18
Return on Assets (ROA)-1.03
Return on Invested Capital (ROIC)400.57%
Return on Capital Employed (ROCE)0.50
Revenue Per Employee0.00
Profits Per Employee-968.10K
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Liminatus Pharma is ―. Liminatus Pharma’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio-2.27
Price to Fair Value-2.27
Price to FCF-11.60
Price to Operating Cash Flow-2.25
PEG Ratio-0.07
Income Statement
In the last 12 months, Liminatus Pharma had revenue of 0.00 and earned -2.90M in profits. Earnings per share was -0.40.
Revenue0.00
Gross Profit0.00
Operating Income-2.91M
Pretax Income-2.89M
Net Income-2.90M
EBITDA-2.75M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was -10.36M and capital expenditures -13.11K, giving a free cash flow of -10.38M billion.
Operating Cash Flow-10.36M
Free Cash Flow-10.38M
Free Cash Flow per Share-0.38
Dividends & Yields
Liminatus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-93.75%
50-Day Moving Average1.05
200-Day Moving Average5.75
Relative Strength Index (RSI)32.88
Average Volume (3m)233.27K
Important Dates
Liminatus Pharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Liminatus Pharma as a current ratio of 0.09, with Debt / Equity ratio of -87.65%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap0.14
Net Debt to EBITDA-1.57
Interest Coverage Ratio-21.04
Taxes
In the past 12 months, Liminatus Pharma has paid 18.84K in taxes.
Income Tax18.84K
Effective Tax Rate>-0.01
Enterprise Valuation
Liminatus Pharma EV to EBITDA ratio is -14.69, with an EV/FCF ratio of -12.99.
EV to Sales0.00
EV to EBITDA-14.69
EV to Free Cash Flow-12.99
EV to Operating Cash Flow-12.99
Balance Sheet
Liminatus Pharma has $724.50K in cash and marketable securities with $1.44M in debt, giving a net cash position of -$718.00K billion.
Cash & Marketable Securities$724.50K
Total Debt$1.44M
Net Cash-$718.00K
Net Cash Per Share-$0.03
Tangible Book Value Per Share-$2.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Liminatus Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―